TumourGraft is an innovative cancer diagnostic test involving the creation of patient-derived xenograft (PDX) models for personalised drug screening. Developed and executed a global launch strategy across the UK, Israel, Singapore, and the USA. After successfully supporting hundreds of cancer patients and publishing results, we pivoted the business model from individual patient services to partnering with pharmaceutical companies for translational research, opening up new revenue streams and enhancing the technology’s long-term viability.
